Florbetapir F-18 is a radiopharmaceutical diagnostic agent used during Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients to diagnose the causes of cognitive impairment. Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide that plays a key role in Alzheimer's...
- Mechanism
- Curator reviewed
Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide that plays a key role in Alzheimer's Disease pathogenesis. The radionucleide fluorine-18 was chosen as it has a half life of 110 minutes allowing it to accumulate sufficiently in the brain before undergoing positon emission decay.
- Primary indication
- Florbetapir 18F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other...Curator reviewed · 1 structured indication
- Formula / weight
- C20H25FN2O3 · 359.432 g/mol (avg)
- First approval
- United States, 2012 · European Union, 2016
- Also known as
- [18F]Florbetapir · Florbetapir (18F) · Florbetapir F18 · florbetapir-fluorine-18
- Code names
- (18F)AV-45 · AV-45 F-18
- Brand names
Resolves to
YNDIAUKFXKEXSV-CRYLGTRXSA-NSMILES[H]N(C1=C([H])C([H])=C(\C([H])=C(/[H])C2=C([H])N=C(OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])[18F])C([H])=C2[H])C([H])=C1[H])C([H])([H])[H]What you can answer from here — as of September 13, 2026
Which drugs share a target with Florbetapir F-18, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account